Albert Labs announces Strategic Investment from Cantheon Capital LLC for First In-Human TrialsMindMed Reports Full Year 2022 Financial Results and Business HighlightsCybin to Participate in the Oppenheimer 33rd Annual Healthcare ConferenceNuminus to Participate in the Sequire Cannabis & Psychedelics Conference on Wednesday, April 5, 2023Braxia Scientific Provides Update on Proposed Irwin Transaction; Company Retains Strategic Clinical Assets and Ketamine Numinus Announces Four Peer-Reviewed Publications from its Chief Clinical Officer in 2023Irwin Naturals Signs Letter of Intent to Acquire Braxia ScientificNuminus Wellness Inc. Reports Q1 2023 ResultsIrwin Naturals and Braxia Scientific Announce Partnership for In-Human Clinical Studies Supporting Pharmaceutical CompanNuminus Develops Mushroom Tea for Use in Psychedelic ResearchIs the Psychedelic Sector Poised for a Comeback?!?PSYC + Nucleus Form New Partnership to Develop and Launch Psychedelic FinderWhat You Need to Know About Numinus Wellness…Numinus provides update on acquisition integration and announces new client financing optionsPSYC Corp’s Psychedelic Spotlight Surpasses One Million Page Views for Fourth Consecutive MonthNuminus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022The Psychedelic Sector is Quietly Outperforming the S&P 500PSYC Completes and Publishes 2021 Audited Financials; Will Begin Audit of Q1 & Q2 2022Numinus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022PSYC’s Bonfire Platform Development Progresses; Will Host Free Virtual Community Event on August 29th
Back

Pure Global Cannabis receives oils licence from Health Canada

Aug 27, 2018 • 2:17 PM EDT
Cannabis (28).png
3 MIN READ  •  By Michael Berger
Share Share - Facebook Share - Twitter

Pure Global Cannabis Inc. (TSX.V:PURE; OTC: PRCNF), a vertically-integrated, growth-oriented life sciences cannabis company, is pleased to announce that its wholly-owned subsidiary, PureSinse Inc. (“PureSinse“), has received approval for an amendment to its licence from Health Canada under the Access to Cannabis for Medical Purposes Regulations (“ACMPR“), to include the activity of possession of cannabis oil, resin, and relevant activities.

Pure Global Cannabis Inc. (CNW Group/Pure Global Cannabis Inc.)

PureSinse’s license under the ACMPR was amended August 24, 2018, allowing the company to source bulk psychoactive and non-psychoactive cannabis oils along with resins from national and international licensed producers that meet Pure Global’s high quality standards. The next step will be to receive Health Canada approvals to process, package, and sell cannabis oil-based products.

The Company anticipates that PureSinse will be granted a cannabis oils production and processing licence by the end of 2018 and subsequent oils sales licence in early 2019. Upon final licensing approval, PureSinse will have the ability to sell cannabis oil products to registered patients under the ACMPR, for adult legal use under the Cannabis Act, and for export purposes, along with its current dried medical cannabis products.

“This license is instrumental for PURE’s ability to initiate revenue generation from oils in the coming quarters, while driving our product innovation, amplifying our intellectual property portfolio, and propelling our research and development mandates for cannabis oils-based products. The Company will look to secure long-term supply agreements for bulk dried flower, extractable trim, and now for cannabis and cannabidiol (CBD) distillates, isolates, and extracts, for processing, packaging, and distribution,” said Pure Global President & CEO Malay Panchal. “We will immediately be applying for our oils production and processing licences to accelerate the development and formulation of cannabis oils products such as gel capsules, tinctures, sublinguals, and transdermal dosage forms,” added Mr. Panchal.

About Pure Global Cannabis

Pure Global Cannabis Inc. (TSX.V:PURE; OTC: PRCNF) is a vertically-integrated, growth-oriented life sciences cannabis company led by experienced pharma-industry, horticultural, consumer packaged goods (CPG), and supply chain experts. The Company’s wholly owned subsidiary, PureSinse Inc., is a licensed producer under the Access to Cannabis for Medical Purposes Regulations (ACMPR) focused on producing cannabis products for medical, wellness, health & beauty, natural health, and future legal adult use markets.

To register to Pure Global’s mailing list, please visit www.pureglobal.com. Follow @pureglobalcanna on Twitter and Facebook and @pureglobalcannabis on Instagram.

FORWARD-LOOKING STATEMENTS

This news release contains certain forward-looking statements, including, but not limited to, statements about Pure Global’s future plans and intentions.  Wherever possible, words such as “may”, “will”, “should”, “could”, “expect”, “plan”, “intend”, “anticipate”, “believe”, “estimate”, “predict” or “potential” or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. These statements reflect management’s current beliefs and are based on information currently available to management as at the date hereof.

Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These factors should be considered carefully, and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this news release are based upon what management believes to be reasonable assumptions, Pure Global cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this news release, and Pure Global assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Pure Global Cannabis Inc.

View original content with multimedia: http://www.newswire.ca/en/releases/archive/August2018/27/c1153.html

regarding Pure Global, please contact: Stephen Pynn, VP Corporate Development, Telephone: 1-866-899-PURE (7873), E-mail: stephen@pureglobal.com; Malay (Mel) Panchal, President & CEO, Telephone: 1-866-899-PURE (7873), E-mail: info@pureglobal.comCopyright CNW Group 2018

Source: Canada Newswire (August 27, 2018 – 9:58 AM EDT)

News by QuoteMedia
www.quotemedia.com

Share Share - Facebook Share - Twitter

Tags

Authored By

Michael Berger

Michael Berger is Managing Partner of StoneBridge Partners, LLC and Founder of Mushroomstocks.com. Prior to entering the cannabis industry, Michael was an Equity Research Analyst at Raymond James Financial covering the Energy Sector. Michael has been featured in publications such as The Street, Bloomberg, US Money News, and hosts various cannabis events across North America.

Comments

Top Stories

Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Mushroomstocks newsletter.

 All good -- no spamming here.

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.
Subscribe
SUBSCRIBE NOW
close-link